ClinicalTrials.gg
CompletedNCT00094081Updated Feb 15, 2010

Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer

A Phase 3 interventional study of tirapazamine (SR259075) and cisplatin in Head and Neck Neoplasms, sponsored by Sanofi. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-15.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
861
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing cisplatin in Head and Neck Neoplasms — 11 open to participants now, 18 under way, 1 of them phase 3. Cisplatin · Head and Neck Neoplasms.

Enrollment
2nd of 119
861 · median 42
Started
2002
with 6 others
Phase 3
11 of 127
none open now
Registered
34th of 127
by date
Lead sponsor
4 of 127
Sanofi

Among the 127 studies testing cisplatin in Head and Neck Neoplasms, this one is the 2nd largest by enrollment of the 119 interventional ones that give a count, is one of 7 that started in 2002, is one of 11 in phase 3, and was the 34th registered.

Head and Neck Neoplasms

2,713 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

11 of the 127 studies testing cisplatin in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing cisplatin in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.

03

Conditions studied

  • Head and Neck Neoplasms

Keywords

  • squamous cell carcinoma
  • oropharynx
  • oral cavity
  • larynx
  • hypopharynx
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.
  • Stage III or IV disease (excluding T1N1, and T2N1).
  • performance status less than or equal to 2.
  • at least 1.5 X 10\^9/L, count at least 100 X 10\^9/L, and > 9g/dL.
  • Serum \< 1.25 times and /ALT \< 2.5 times ULN.
  • Calculated (Cockcroft-Gault) > 55 mL/min.

Exclusion criteria

Exclusion Criteria:

  • Disease
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
861 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival.

Secondary outcomes

  1. Time to locoregional failure.

07

Study locations

10 sites
  • Foundation for Cancer Research and Education
    Phoenix, Arizona 85013, United States
  • Stanford University Medical Center
    Palo Alto, California 94305, United States
  • H-Lee Moffitt Cancer Center and Research
    Tampa, Florida 33612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21231, United States
  • Harper Hospital
    Detroit, Michigan 48201, United States
  • VA New Jersey Health Care Medical Center
    East Orange, New Jersey 07018, United States
  • University of Rochester Medical Center
    Rochester, New York 14620, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
08

References and documents

Publications

  • Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Nuyts S, Wratten C, Rischin D. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):678-686. doi: 10.1016/j.ijrobp.2016.03.017. Epub 2016 Mar 23. Erratum In: Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):244. doi: 10.1016/j.ijrobp.2017.05.042. PubMed 27209505 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2004
First posted
Oct 14, 2004
Start
Oct 2002
Primary completionActual
Sep 2006
CompletionActual
Sep 2006
Last update
Feb 15, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00094081
Lead sponsor
Sanofi
First posted
Oct 14, 2004
Start date
Oct 2002
Primary completion
Sep 2006
Completion
Sep 2006
Last update
Feb 15, 2010

Study contacts

ICD CSD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tirapazamine · Cisplatin

Start the discussion